NCT06718751View on ClinicalTrials.gov

Tranexamic Acid Therapy For The Treatment of Subdural Hematomas

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2029

Study Completion Date

October 31, 2030

Conditions
Chronic Subdural Hematoma
Interventions
DRUG

Tranexamic Acid 650 MG

PO administration of TXA tablet

DRUG

Placebo

PO administration of placebo tablet

All Listed Sponsors
lead

Baylor College of Medicine

OTHER

NCT06718751 - Tranexamic Acid Therapy For The Treatment of Subdural Hematomas | Biotech Hunter | Biotech Hunter